Saturday 17 October 2026
Export LSDIF’s income statement to Excel — free account
Lucy Scientific Discovery Inc.
LSDIF Healthcare Drug Manufacturers Specialty & Generic
Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow LSDIF
| Jun '20 | Jun '21 | Jun '22 | Jun '23 | |
|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 |
Altman Z-Score |
— | — | — | (6.99) |
P/S ratio |
— | — | — | 0.00 |
P/FCF ratio |
— | — | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | (18.94) |
P/Operating CF |
— | — | — | (7.85) |
P/B ratio |
— | — | — | 3.12 |
Price to Tangible BV |
— | — | — | 4.57 |
EV/Sales |
— | — | — | 0.00 |
EV/EBITDA |
— | — | — | 0.00 |
EV/Operating CF |
— | — | — | (3.36) |
EV/FCF |
— | — | — | (3.39) |
Quick Ratio |
0.02 | 0.05 | 0.01 | 0.74 |
Current Ratio |
0.03 | 0.07 | 0.33 | 1.41 |
Net Debt/EBITDA |
(0.43) | (0.73) | (0.86) | 0.29 |
Debt/Assets |
1,063.32% | 39.45% | 65.38% | 0.00% |
Debt/Equity |
(0.29) | (0.34) | (0.63) | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.17 | 0.31 | 0.41 | 0.47 |
Capex/Depreciation |
— | — | (3.31) | (2.48) |
Interest Coverage |
(33.31) | (2.27) | (1.68) | (2.97) |
| 0.00% | 88.39% | 105.19% | 18,140.26% | |
| 0.00% | (166.57%) | (114.98%) | (134.06%) | |
ROIC |
0.00% | 0.00% | 0.00% | (121.55%) |
Return on Tangible Assets |
82.72% | 131.27% | 190.88% | (478.88%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 17,926.71 |
Research and Development Expense of Revenue |
0.00% | — | — | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 82,398.57% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.17 |
Share Based Compensation of Revenue |
— | — | 0.00% | 13,587.14% |
Graham Net Nets |
— | — | — | (0.02) |
Graham Number |
— | — | — | 0.00 |
Earnings Yield |
— | — | — | (61.49%) |
Free Cash Flow Yield |
— | — | — | (28.98%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.01 |
Operating CF per Share |
(0.03) | (0.09) | (2.81) | (3.36) |
Capex per Share |
0.00 | 0.00 | (0.04) | (0.21) |
Free Cash Flow per Share |
(0.03) | (0.09) | (2.85) | (3.57) |
Cash per Share |
0.00 | 0.02 | 0.06 | 1.32 |
Shareholders Equity per Share |
(0.27) | (0.40) | (5.55) | 3.68 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.27) | (0.40) | (5.55) | 3.68 |
Free Cash Flow |
(0.50) | (1.48) | (2.45) | (4.53) |
Working Capital |
(3.63) | (4.44) | (3.91) | 1.11 |
Capital Expenditures |
— | — | (0.03) | (0.27) |
Net Current Asset Value |
(4.36) | (11.58) | (7.51) | (0.28) |
EV/EBIT |
— | — | — | 0.00 |
Capex to Sales |
— | — | 0.00 | 37.99 |
Price to Operating Income |
— | — | — | 0.00 |
| Other line items | ||||
Depreciation/Fixed assets |
— | 0.00 | 0.01 | 0.14 |
Cash ROIC |
16.54% | 37.88% | 144.58% | (71.34%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.04 |
Accounts Payable Turnover |
— | — | — | 0.00 |
Inventory Turnover |
— | — | — | 0.00 |
Average Days of Payables |
— | — | 0.00 | 104,722.56 |
Days of Inventory on Hand |
— | — | — | 0.00 |
Average Receivables |
— | 0.01 | 0.01 | 0.18 |
Average Payables |
— | — | — | 2.05 |
Average Assets |
— | 2.84 | 5.09 | 6.71 |
Average Common Equity |
— | (5.35) | (5.57) | (0.05) |
Columns are period end dates